Effectiveness, safety and costs of thromboembolic prevention in patients with non-valvular atrial fibrillation: phase I ESC-FA protocol study and baseline characteristics of a cohort from a primary care electronic database.
Maria Giner-SorianoCristina Vedia UrgellAlbert Roso-LlorachRosa MorrosDolors CapellàXavier CastellsIgnacio Ferreira-GonzálezAmelia Troncoso MariñoEduard DiògeneJosep M ElorzaMarc CasajuanaBonaventura BolíbarConcepció ViolanPublished in: BMJ open (2016)
The next phase in the ESC-FA study will involve assessing the effectiveness and safety of antithrombotic treatments, analysing stroke events and bleeding episodes' rates in our patients (rest of phase I), describing the current management of the disease and its costs in our setting, and assessing how the introduction of new oral anticoagulants changes the stroke prevention in non-valvular atrial fibrillation.
Keyphrases
- atrial fibrillation
- oral anticoagulants
- catheter ablation
- left atrial
- left atrial appendage
- direct oral anticoagulants
- primary care
- heart failure
- percutaneous coronary intervention
- randomized controlled trial
- ejection fraction
- systematic review
- newly diagnosed
- end stage renal disease
- emergency department
- acute coronary syndrome
- coronary artery disease
- left ventricular